Power3 Medical Products, Inc. Provides Results from 60 Patient Blinded Validation Study of BC-SeraPro™

HOUSTON--(BUSINESS WIRE)--Power3 Medical Products, Inc. (OTC: PWRM), a leading proteomics company specializing in the development and commercialization of early detection diagnostic tests for breast cancer and neurodegenerative disease, has concluded a 60 patient blinded validation study of its BC-SeraPro™ early detection blood serum breast cancer test.

“Breast cancer is the most common malignancy among women and the second leading cause of cancer deaths in women in the United States. It is now known that women born in the United States have, on average, a 12.6%, or one in eight chance of developing Breast cancer.”

For the study, Power3 used its extensive patient serum sample bank to generate a statistical model that differentiates between breast cancer and control profiles. Sixty blinded patient samples were then tested against this statistical model. The samples were provided by Mercy Women's Center under the direction of Dr. Alan Hollingsworth, a member of the Company’s Scientific Advisory Board. Twenty-two biomarkers were used to obtain the results from this study.

By applying decision tree analysis, a method used to model disease and control patient demographics at the level of individual biomarkers, Power3 reported results of 97% sensitivity and 93% specificity. In addition, the Company used Linear Discriminant Analysis, a more robust and flexible method that uses some or all biomarkers in a panel rather than individually, which achieved 80% sensitivity and 87% specificity.

“These results are a major step forward in commercializing the BC-SeraPro™ diagnostic for the early detection of breast cancer. We are finalizing the development program and moving forward with our strategy of providing a test that is utilitarian, accurate, and inexpensive. Detection of a patient’s protein biomarker profile can now be employed to detect abnormal and pathological states reflected in the serum proteome. With this in mind, application of this test may have a future impact on how disease will be diagnosed, monitored, and managed,” commented Steven Rash, Chief Executive Officer of Power3 Medical.

Mr. Rash continued, “Breast cancer is the most common malignancy among women and the second leading cause of cancer deaths in women in the United States. It is now known that women born in the United States have, on average, a 12.6%, or one in eight chance of developing Breast cancer.”

In addition to the BC-Sera Pro™ test, Power3 is currently evaluating its NuroPro® early detection blood serum test for Parkinson’s disease in a 500 patient validation study with the University of Thessaly Medical School in Greece. The Company’s NuroPro® early detection blood serum test for Alzheimer’s disease is in the final stages of development and is transitioning into the commercialization stage.

About Power3 Medical Products

Power3 Medical Products, Inc. (www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company’s identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as Breast Cancer and neurodegenerative disease. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas, and recently announced an agreement forming a joint venture (CRO) with NeoGenomics, Inc. (NASDAQ: NGNM - News) of Fort Myers, Florida, to commercialize Power3's portfolio of IP, centering on the 534 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for Breast Cancer, ALS, Alzheimer's and Parkinson's Diseases.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.